Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo
Byeong‐Woo Park(University Health System), Ramachandran Murali(The Wistar Institute), Donald M. O’Rourke(University of Pennsylvania), Xin Zhang(University of Pennsylvania), Hongtao Zhang(Chinese Academy of Sciences), Qiang Wang(Cedars-Sinai Medical Center), Mark I. Greene, Gary D. Kao(University of Pennsylvania), Alan Berezov, Raj Dua, Chuan-Jin Wu(University of Pennsylvania)
Cited by 200
Related Papers
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578
Advances in clinical immunotherapy for gastric cancer
|Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|2021|435
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
|Neuro-Oncology|2018|314